Switchback Systems

What Switchback Systems does

Switchback Systems is an early-stage, venture-backed biotechnology company headquartered in the San Francisco Bay Area that is developing a proprietary benchtop DNA synthesis platform intended to replace outsourced DNA synthesis services with in-house, plug-and-play instrumentation. The company was founded in 2019 and emerged as the first portfolio company of the General Inception Venture Studio, subsequently attracting capital from OMX Ventures, Vertical Venture Partners, and Ahren Innovation Capital, with cumulative disclosed equity raises of approximately $18.4M across SEC Form D filings in 2020, 2023, and 2024. The Switchback Platform integrates onboard oligonucleotide synthesis and gene assembly into a single self-contained benchtop unit, positioning the product against four identified pain points of incumbent service models: turnaround time, sequence fidelity, cost, and confidentiality. The company targets a multi-vertical customer base spanning pharmaceuticals, gene therapy, agriculture, diagnostics, cancer treatments, and aquaculture, and pursues a direct enterprise field-sales motion with a hardware revenue model.

The team remains small (1-10 employees) under founder and CEO Mary Noe, with no publicly disclosed pricing, no named reference customers, and a careers page showing no open roles, signaling a company still in pre-commercial or pilot commercialization. Distribution is described as global in scope via direct enterprise engagement, though no concrete geographic footprint beyond the U.S. headquarters is documented. The core go-to-market thesis — that on-premises synthesis will win share from outsourced service providers by reducing cost, accelerating turnaround, and protecting IP — is the central commercial bet underpinning the company's continued capital raises.

Name

Switchback Systems

Legal name

Switchback Systems, Inc.

Website

https://switchbacksys.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Switchback Systems is an early-stage San Francisco-based biotechnology company developing a proprietary benchtop DNA synthesis platform that integrates oligonucleotide synthesis and gene assembly to replace outsourced DNA synthesis services for pharmaceutical, gene therapy, agricultural, and diagnostics customers.

Ownership category

akta.pro rank

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Benchtop DNA Synthesis Platform Sales: Sale of the proprietary benchtop DNA synthesis hardware platform to life science companies, research institutions, and biotech firms. The self-contained system with onboard synthesis and assembly capabilities represents the primary revenue driver.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Switchback Systems develops and sells a proprietary benchtop DNA synthesis platform that combines oligonucleotide synthesis and gene assembly in a single self-contained instrument. The plug-and-play system is sold to life science companies and research institutions as an in-house alternative to outsourced DNA synthesis services.

Product overview

Switchback Systems offers a single unified product: the Switchback Platform, a benchtop DNA synthesis system. This self-contained platform combines oligonucleotide synthesis and gene assembly capabilities in one device, eliminating the need for traditional outsourced service models. The company positions it as a democratizing tool that places synthetic biology capabilities directly in scientists' hands.

Differentiator

Problem solved

Functional benefit

Products and services

• Switchback Platform

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• DNA Script: DNA Script develops enzymatic benchtop DNA synthesis systems (SYNTAX platform) that allow labs to synthesize oligonucleotides on demand. It is the closest direct peer to Switchback in terms of product architecture (benchtop, in-lab synthesis), customer base (life sciences and pharma), and go-to-market (instrument plus consumables).
• Evonetix: Evonetix is developing a benchtop DNA synthesis platform using a silicon chip-based approach to produce high-fidelity oligonucleotides in-house. Like Switchback, it targets research and pharma customers seeking decentralized, rapid DNA synthesis, making it a direct peer in the benchtop synthesis category.
• Codex DNA (formerly Synthetic Genomics): Codex DNA develops synthetic biology tools including benchtop biofoundry systems for gene and genome assembly, targeting similar customers as Switchback in pharma, vaccines, and cell engineering. It is a direct competitor in the benchtop synthetic biology workflow category.

Broad incumbents

• Twist Bioscience: Twist Bioscience is the leading commercial-scale DNA synthesis provider, offering high-throughput gene and oligo synthesis on a silicon platform. While Twist is a centralized service rather than benchtop, it is the dominant incumbent whose outsourced model Switchback is seeking to disrupt.
• Integrated DNA Technologies (IDT): IDT is one of the largest commercial suppliers of custom oligonucleotides and synthetic biology products, serving pharma, academic, and diagnostics customers globally. It represents the entrenched outsourced service model that Switchback's benchtop platform aims to replace for in-house workflows.
• GenScript: GenScript provides gene synthesis, oligo synthesis, and a broad portfolio of life science research services and reagents. It competes with Switchback in providing DNA synthesis solutions to pharma, biotech, and academic customers, though primarily through outsourced services.
• Eurofins Genomics: Eurofins Genomics offers outsourced gene synthesis, oligo synthesis, and broader genomic services to life sciences customers globally. It represents the legacy outsourced service model that Switchback's in-house platform directly competes against.

Emerging players

• Ansa Bio: Ansa Bio is developing an enzymatic DNA synthesis platform aimed at enabling rapid, high-quality gene synthesis. It targets the same application space as Switchback (synthetic biology, gene therapy, pharma) and represents an emerging competitor in next-generation synthesis technologies.
• Camena Bioscience: Camena Bioscience is building enzymatic DNA synthesis technology for high-fidelity gene synthesis, with applications in therapeutics and industrial biotechnology. It overlaps with Switchback in technology approach (next-gen synthesis) and target customers (biotech and pharma).
• Molecular Assemblies: Molecular Assemblies is developing an enzymatic DNA synthesis technology aimed at producing long, high-fidelity oligonucleotides for synthetic biology applications. It is an emerging peer targeting similar customer use cases in pharma and synthetic biology as Switchback.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/switchback-sys

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Switchback Systems